Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Complications

Early complications following haematopoietic SCT in children

Bone Marrow Transplantation volume 41, pages S39–S42 (2008)Cite this article

Abstract

Early complications can be defined as those occurring within 100 days after transplant. Both epithelial and endothelial damage represent the pathogenetic basis for the onset of the most frequent complications. Clinical features related to endothelial damage depend on the involved district or on the grade and type of general distribution. Veno-occlusive disease (VOD) most often occurs within the first 20 days of haematopoietic SCT (HSCT) and is characterized by the obstruction of small intrahepatic venules and is caused by an initial injury of the sinusoid endothelial cells. The incidence in children ranges between 27 and 40%, and symptoms include hepatomegaly, portal hypertension and ascites. Early intervention with defibrotide (DF) proved to be effective for the treatment; however, overall mortality ranges between 20 and 50%. Thrombotic microangiopathy (TAM) incidence is 4–13%. It is often associated with the use of CYA or tacrolimus, and symptoms include haemolytic anaemia, thrombocytopenia and renal and/or central nervous system impairment. Treatment includes plasmapheresis and supportive care. The promising role of DF needs to be confirmed. The onset of engraftment syndrome may occur 1 or 2 days before the neutrophil count in peripheral blood increases. Clinical symptoms include fever not related to infection, respiratory involvement with pulmonary infiltrates or hypoxia and skin rash. Treatment consists of steroid administration for a few days. Haemorrhagic cystitis (HC) may occur early or later following transplant. Early-onset HC is related to mucosal damage caused by the catabolites of chemotherapy drugs, and late-onset HC is mostly caused by viral infections. The incidence ranges between 1 and 25%. Clinical symptoms include haematuria and dysuria without infections. Treatment includes hyperhydration and platelet support. In case of vescical clots, bladder irrigation is indicated. In advanced cases, hyperbaric oxygen administration or surgery may be useful. The use of cidofovir for BK virus-related HC seems encouraging, but further studies are needed to confirm its real efficacy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB . Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19: 1171–1181.

    Article  CAS  PubMed  Google Scholar 

  2. Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996; 37: 247–253.

    Article  CAS  PubMed  Google Scholar 

  3. Hasegawa S, Horibe K, Kawabe T, Kato K, Kojima S, Matsuyama T et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transplant 1998; 22: 1191–1197.

    Article  CAS  PubMed  Google Scholar 

  4. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599–3604.

    CAS  PubMed  Google Scholar 

  5. Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB . Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Marrow Transplant 1999; 5: 306–315.

    Article  CAS  Google Scholar 

  6. Stadtmauer EA, Larson RA, Sievers E, Estey E, Lowenberg B, Leopold LH et al. Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozagamicin (Mylotarg, CMA-676). Blood 2001; 98: 124A.

    Google Scholar 

  7. DeLeve LD, Shulman HM, Mc Donald GB . Toxic injury to hepatic sinusoid: Sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27–42.

    Article  PubMed  Google Scholar 

  8. Salat C, Holler E, Kolb HJ, Pihusch R, Reinhardt B, Penovici M et al. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. Leuk Lymphoma 1999; 33: 25–32.

    Article  CAS  PubMed  Google Scholar 

  9. Rio B, Bauduer F, Arrago JP, Zittoun R . N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 1993; 11: 471–472.

    CAS  PubMed  Google Scholar 

  10. Eltumi M, Trivedi P, Hobbs JR, Portmann B, Cheeseman P, Downie C et al. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 1993; 342: 518–521.

    Article  CAS  PubMed  Google Scholar 

  11. Heikinheimo M, Halila R, Fasth A . Serum procollagen type III is an early and sensitive marker for veno- occlusive disease of the liver in children undergoing bone marrow transplantation. Blood 1994; 83: 3036–3040.

    CAS  PubMed  Google Scholar 

  12. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122–1129.

    Article  CAS  PubMed  Google Scholar 

  13. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, et al., European Group for Blood and Marrow Transplantation; European LeukemiaNet. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95–100.

    Article  PubMed  Google Scholar 

  14. Daly AS, Xenocostas A, Lipton JH . Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant 2002; 30: 709–715. Review.

    Article  CAS  PubMed  Google Scholar 

  15. Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS . Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 1995; 15: 247–253.

    CAS  PubMed  Google Scholar 

  16. Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M et al. Risk factors and severe outcome in Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation 2006; 82: 638–644.

    Article  PubMed  Google Scholar 

  17. Spitzer TR . Engraftment syndrome following haematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893–898.

    Article  CAS  PubMed  Google Scholar 

  18. Gorczynska E, Turkiewicz D, Rybka K, Toporski J, Kalwak K, Dyla A et al. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 797–804.

    Article  PubMed  Google Scholar 

  19. Cesaro S, Brugiolo A, Faraci M, Uderzo C, Rondelli R, Favre C et al. Incidence and treatment of hemorrhagic cystitis in children given hematopoietic stem cell transplantation: a survey from the Italian association of pediatric hematology oncology-bone marrow transplantation group. Bone Marrow Transplant 2003; 32: 925–931.

    Article  CAS  PubMed  Google Scholar 

  20. Hale GA, Rochester RJ, Heslop HE, Krance RA, Gingrich JR, Benaim E et al. Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. Biol Blood Marrow Transplant 2003; 9: 698–705.

    Article  CAS  PubMed  Google Scholar 

  21. Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL . Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood 2001; 98: 1971–1978.

    Article  CAS  PubMed  Google Scholar 

  22. Droller MJ, Saral R, Santos G . Prevention of cyclophosphamide-induced hemorragic cystitis. Urology 1982; 20: 256–258.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department Haematology/Oncology, G. Gaslini Children's Research Institute, Genoa, Italy

    M Miano, M Faraci & G Dini

  2. Department of Pediatrics, Hopital d'Enfants, Vandeouvre Les Nancy, France

    P Bordigoni

Authors
  1. M Miano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Faraci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Dini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Bordigoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the EBMT Paediatric Working Party

Corresponding author

Correspondence to M Miano.

Additional information

Conflict of interest

None of the authors declared any financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miano, M., Faraci, M., Dini, G. et al. Early complications following haematopoietic SCT in children. Bone Marrow Transplant 41 (Suppl 2), S39–S42 (2008). https://doi.org/10.1038/bmt.2008.53

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.53

Keywords

This article is cited by

Search

Advanced search

Quick links